Related Experiment Videos
Acceleration of reverse cholesterol transport
A von Eckardstein1, J R Nofer, G Assmann
1Institut für Klinische Chemie und Laboratoriumsmedizin, Zentrallaboratorium, Westfälische Wilhelms-Universität Münster, Germany. vonecka@uni-muenster.de
Insights
Low high-density lipoprotein (HDL) cholesterol increases coronary heart disease risk. Enhancing cholesterol removal from arteries is a therapeutic target, but HDL levels may not always indicate treatment effectiveness.
Area of Science:
- Cardiovascular Science
- Lipid Metabolism
- Atherosclerosis Research
Background:
- Low high-density lipoprotein (HDL) cholesterol is a significant risk factor for coronary heart disease (CHD).
- HDL cholesterol levels and subclass composition are influenced by numerous biological factors.
- Reverse cholesterol transport (RCT) via HDL is crucial for preventing atherosclerosis.
Purpose of the Study:
- To investigate the relationship between HDL cholesterol levels and the efficacy of reverse cholesterol transport.
- To evaluate RCT as a therapeutic target for anti-atherosclerotic drug development.
Main Methods:
- Analysis of factors regulating HDL cholesterol and its subclasses.
- Assessment of reverse cholesterol transport mechanisms from arterial wall cells to the liver.
Main Results:
- Serum HDL cholesterol levels may not accurately reflect the efficiency of reverse cholesterol transport.
- HDL's anti-atherogenic properties are linked to its role in RCT.
Conclusions:
- Targeting RCT enhancement holds potential for anti-atherosclerotic therapies.
- Relying solely on serum HDL cholesterol levels may be insufficient to gauge therapeutic success in RCT enhancement.
Abstract:
A low level of high-density lipoprotein (HDL) cholesterol is an important risk factor for coronary heart disease. Levels of HDL cholesterol and composition of HDL subclasses in plasma are regulated by many factors, including apolipoproteins, lipolytic enzymes, lipid transfer proteins, receptors, and cellular transporters. Reverse transport of cholesterol from cells of the arterial wall to the liver is an important mechanism by which HDL exerts its anti-atherogenic properties. Enhancement of reverse cholesterol transport is considered as a potential target for anti-atherosclerotic drug therapy. It is suggested, however, that the serum level of HDL cholesterol does not necessarily reflect the efficacy of reverse cholesterol transport.